» Articles » PMID: 18591575

Apathy Associated with Alzheimer Disease: Use of Dextroamphetamine Challenge

Overview
Publisher Elsevier
Specialty Geriatrics
Date 2008 Jul 2
PMID 18591575
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the role of the dopaminergic brain reward system (BRS) in apathy associated with Alzheimer disease (AD).

Design: BRS function was probed in 20 AD patients using dextroamphetamine (d-amph) challenge. After baseline behavioral testing, patients were given a single 10 mg dose of d-amph. The time course of the subjective response to d-amph was assessed at hourly intervals for 4 hours.

Setting: Three outpatient dementia clinics associated with a university-affiliated hospital.

Participants: Twenty AD patients aged 77 +/- 8 years with Neuropsychiatric Inventory (NPI) apathy scores of 3.4 +/- 3.5 and Mini-Mental State Examination scores of 20.4 +/- 5.1.

Measurements: Patients were classified as apathetic based on an NPI apathy subscore of > or =4. Apathy severity was assessed using the Apathy Evaluation Scale (AES). The subjective and behavioral responses to d-amph were assessed using computerized versions of the Addiction Research Centre Inventory (ARCI), Profile of Mood States and Connor's Continuous Performance Task.

Results: Repeated measures ANOVA revealed a significant interaction between the presence of apathy and the peak subjective response to d-amph on the ARCI, such that while nonapathetic AD patients were responsive to the rewarding effects of d-amph, apathetic patients were not (F(1,17) = 4.93, p = 0.04). Continuous AES scores were predicted by peak ARCI positive effects scores and baseline overall behavioral disturbances (NPI total) in a backward linear regression analysis using the entire study sample (F(2,17) = 10.00, p = 0.01, R(2) = 0.49).

Conclusions: Apathy in AD is associated with a blunted subjective response to d-amph, which may be indicative of dysfunction in the BRS.

Citing Articles

Elevated plasma total homocysteine levels are associated with behavioral and psychological symptoms in dementia with Lewy bodies.

Zhang G, Liu S, Xu Y, Ma L, Zhang W, Ji Y Front Neurosci. 2024; 18:1406694.

PMID: 39628654 PMC: 11611840. DOI: 10.3389/fnins.2024.1406694.


Advances in Brain Stimulation, Nanomedicine and the Use of Magnetoelectric Nanoparticles: Dopaminergic Alterations and Their Role in Neurodegeneration and Drug Addiction.

Gimenez S, Millan A, Mora-Morell A, Ayuso N, Gastaldo-Jordan I, Pardo M Molecules. 2024; 29(15).

PMID: 39124985 PMC: 11314096. DOI: 10.3390/molecules29153580.


An Update on Apathy in Alzheimer's Disease.

Dolphin H, Dyer A, McHale C, ODowd S, Kennelly S Geriatrics (Basel). 2023; 8(4).

PMID: 37489323 PMC: 10366907. DOI: 10.3390/geriatrics8040075.


Biomedical knowledge graph learning for drug repurposing by extending guilt-by-association to multiple layers.

Bang D, Lim S, Lee S, Kim S Nat Commun. 2023; 14(1):3570.

PMID: 37322032 PMC: 10272215. DOI: 10.1038/s41467-023-39301-y.


Apathy in Parkinson's Disease: Defining the Park Apathy Subtype.

De Waele S, Cras P, Crosiers D Brain Sci. 2022; 12(7).

PMID: 35884730 PMC: 9313138. DOI: 10.3390/brainsci12070923.